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1 ABSTRACT 
1.1 SUMMARY  
Skin sensitization is the development of the allergic contact dermatitis caused by chemicals. Regulatory 
accepted methods to assess skin sensitizing potential of chemicals are animal based tests, but increasing interest 
in animal welfare presses the development of animal-free methods. The aim of this work was the development, 
establishment and validation of several alternative methods to animal testing to predict the skin sensitizing 
potential of chemicals. Therefore several methods reflecting different parts of the complex sensitization process 
have been used. Three steps of the skin sensitizing process were depicted: protein reactivity of chemicals, 
activation of keratinocytes and dendritic cell like cells have been investigated. Establishment and validation of 
the methods was performed with 54 test substances of known sensitizing potential, and the findings were 
compared to available human patch test data and murine local lymph node assay data. The experimental data 
were used to calculate the predictivity of each assay in order to compare the several assays and as well to 
evaluate possible combinations. By combination of different assays or more specifically the combination of the 
outcome of different assay into a testing strategy or testing battery predictivities were increased and allowed the 
prediction of sensitizing and non-sensitizing substances with high probability.  
The development of new methods to predict the protein reactive potential of sensitizing substances indicated 
that such compounds are able to react with proteins on the cell surface and that this reaction impacts the 
detection of such proteins by antibody staining. After treatment with sensitizing substances less protein was 
detectable and two hypotheses were proposed and investigated: It was shown that antibody binding was reduced 
or fully inhibited but also that the internalization of the altered protein was triggered. A correlation between the 
sensitizing potential and the altered protein level was confirmed although the underlying mechanism of how 
detectable protein level were reduced remained to be not fully understood. Further investigations are still 
required as the expression of the used protein in this study is up-regulated during the activation of dendritic 
cells. This phenomenon was observed for three out of five sensitizing substances.  
This work represents successful validations, inter- and intra-laboraty, of several animal-free test methods. The 
combinations of assays showed that predictivity compared to single assays can be increased and that for the 
number of tested substances these combinations are comparable to the local lymph node assay, the current gold 
standard to assess skin sensitizing potential. Although this work was no part of the formal validation of these 
assays, increased acceptance was gained, showing the reliability, reproducibility and high predictivities of these 
assays. The work on a new cell based protein reactivity assay showed a correlation between reduced level of 
detectable protein and the exposure of cells with sensitizers, although more investigation is required. The 
expression of the chosen protein unfortunately seemed to be up-regulated under the presence of skin sensitizer. 
Investigation of proteins their expression is independent of cell activation may provide more stable results.  
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1.2 ZUSAMMENFASSUNG 
Die Entstehung der Allergischen Kontaktdermatitis ist besser bekannt als Hautsensibilisierung welche durch 
Chemikalien ausgelöst wird. Um das sensibilisierende Potential der Chemikalien zu untersuchen sind zur Zeit 
nur an Tieren durchgeführte Methoden regulatorisch zugelassen. Mit wachsendem Tierschutzinteresse wird die 
Entwicklung neuer, versuchtierfreier Methoden gefordert. Das Ziel dieser Arbeit war die Entwicklung, 
Etablierung und Validierung verschiedener Methoden, welche als Ersatz zu Tierversuchsmodellen zur 
Vorhersage eines hautsensibilisierenden Potentials von Chemikalien eingesetzt werden sollen. Hierfür wurden 
drei verschiedene Teilschritte des komplexen Prozesses der Hautsensibilisierung in verschiedenen Methoden 
abgebildet. Dabei wurden die Proteinreaktivität von Chemikalien und die Aktivierung von Keratinozyten sowie 
von Dendritschen Zellen untersucht. Die Etablierung und Validierung wurden anhand einer Auswahl von 
insgesamt 54 Substanzen durchgeführt und die Ergebnisse mit verfügbaren humanen Patch-Test Daten bzw. 
Daten aus dem Maustest, lokaler Lymphknotetest, verglichen. Mit diesem Vergleich konnten die Prädiktivitäten 
der einzelnen Methoden berechnet werden, so dass die Methoden untereinander verglichen und sinnvolle 
Kombinationen identifiziert werden können. Die Kombinationen einzelner Methoden bzw. der Ergebnisse der 
Methoden zu einer Teststrategie oder -batterie erhöhte die Prädiktivitäten im Vergleich zu einzelnen Methoden 
und ermöglichte es, eine Vorhersage von sensibilisierenden bzw. nicht-sensibilisierenden Substanzen mit hohen 
Wahrscheinlichkeiten zu treffen.  
Die Entwicklung einer neuer Methoden zur Vorhersage des proteinreaktiven Potentials zeigte, das 
sensibilisierenden Substanzen mit Proteinen an der Zelloberfläche reagieren und Effekte auf die Detektion von 
Zelloberflächenmolekülen mittels Antikörperfärbung haben können. Nach Behandlung der Zellen mit 
sensibilisierenden Substanzen konnte weniger Protein an der Zelloberfläche festgestellt werden. Hierzu wurden 
zwei unterschiedliche Hypothesen aufgestellt und experimentell überprüft. Es wurde gezeigt, dass die Reaktion 
von Chemikalien mit Proteinen an der Zelloberfläche die Bindung von Antikörpern reduziert oder vollständig 
inhibiert, aber auch die Internalisierung des veränderten Proteins auslöst. Ein Zusammenhang zwischen der 
sensibilisierenden Eigenschaft von Chemikalien und der reduzierten nachweisbaren Proteinmenge wurde 
gezeigt, obwohl der Mechanismus welcher der Reduktion des nachweisbaren Proteins zu Grunde liegt nicht 
vollständig geklärt werden konnte. Nicht sensibilisierende Substanzen hatten keinen Effekt auf den 
nachweisbaren Proteingehalt. Weitere Untersuchungen sind nötig, da die Expression des untersuchten Proteins 
mit Aktivierung dendritischer Zellen hochreguliert werden kann. Diese Phänomen wurde bei drei von fünf 
sensibilisierenden Substanzen beobachtet.  
Diese Arbeit zeigte die erfolgreiche Validierungen verschiedener versuchstierfreier Methoden, welche zum 
einen intern aber auch teilweise mit externen Laboren als Ringstudien durch geführt wurde. Es hat sich gezeigt, 
dass die Kombination dieser Methoden die Aussagekraft im Vergleich zu den einzelnen Methoden erhöht hat 
und, für die Anzahl der getesteten Substanzen, vergleichbare Werte zum Standardtest, dem Lokalen 
Lymphknoten Test, erzielt wurden. Obwohl diese Ringversuche nicht Teil der offiziellen Validierung der 
einzelnen Tests waren, wurde die Anerkennung durch die gezeigte Zuverlässigkeit, Reproduzierbarkeit und 
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hohe Prädiktivitäten erhöht. Die Entwicklung eines neuen zellbasierten Tests zur Untersuchung der 
Proteinreaktivität zeigte, dass es einen Zusammenhang zwischen der erniedrigten, messbaren Menge des 
Proteins und der Behandlung der Zellen mit Sensibilisierer gibt, dennoch sind weitere Experimente nötig. Die 
Expression des gewählten Proteins wurde teilweise durch die Behandlung mit Sensibilisierer hoch reguliert. 
Proteine, deren Expression unabhängig von aktivierten Zellen ist, ergeben möglicherweise stabilere Ergebnisse.  
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2 INTRODUCTION 
The use of animal-free methods to predict the hazard and risk of chemicals, such as their skin sensitizing 
potential, is becoming more and more important due to public interest in animal welfare and the demands by 
legal bodies. The scientific knowledge of underlying cellular processes and responses allows the description, 
development and establishment of new methods. Before a newly developed method can be used for regulatory 
purposes the validity and accuracy has to be proven, which are time consuming processes. In case of skin 
sensitization several cellular processes are involved which are unlikely to be sufficiently reflected in a single 
alternative method. The process of skin sensitization can be reflected using cell based assays, but also computer 
based structural analyses of chemicals and cell-free approaches. The challenge of development of animal-free 
test methods is not only the establishment of several assays to rebuild the process of sensitization in vitro but 
also to obtain reliable analyses and judgment of the sensitizing potential of chemicals. 
2.1 ALLERGIC CONTACT DERMATITIS AND CHEMICAL ALLERGENS 
Chemicals can be the trigger of allergic contact dermatitis (ACD), also known as contact allergy. The 
characteristic skin condition is noticeable with symptoms such as rash or skin lesions, itchiness, ooze or drain 
and appearance of blisters and desquamation or redness of the skin. ACD and occurring symptoms can range 
from light to severe reactions (Hostynek and Maybach 2004; Pezutto et al. 2006; Rustemeyer et al. 2006). ACD 
is a type IV allergic reaction of the skin mediated by T cells and triggered by industrial chemicals, cosmetics or 
hygienic products or one of their ingredients (Coombs and Gell 1975; Krasteva et al. 1999). ACD is a two-
phase-process, consisting of development and elicitation. The development of ACD is also called skin 
sensitization and occurs upon first contact with the allergen and proceeds without any noticeable symptoms 
(Saint-Mezard et al. 2004). The elicitation, the actual clinical manifestation of ACD, occurs after the completed 
sensitization phase and with repeated contact to the allergen (Saint-Mezard et al. 2004). Once sensitized to a 
chemical, ACD will last for a lifetime. Today, there is no cure for ACD, however, important aspects in the 
treatment of this condition and prevention of the outbreak are to identify and to avoid the allergen (Peiser et al. 
2012; Schnuch et al. 2008; Uter et al. 2006). ACD entails high impact on work and social life (Hutchings et al. 
2001), hence there is a high interest by government and industry for safe handling of raw materials by workers 
and risk-free use of finished products for consumers (Kimber et al. 2002a; Smith-Pease 2003). Nowadays about 
15 – 20 % of the population suffer from ACD, mainly people in the Western world, with an increasing tendency 
(Thyssen et al. 2007; Zug et al. 2009). Risk factors for the development of ACD are sex, age and genetic 
predisposition, where the repeated contact with low molecular weight allergens at the workplace or with the use 
of consumer products is the main trigger (Ngyen et al. 2008; Peiser et al. 2012; Smith-Pease 2003). Prominent 
examples for skin sensitizing chemicals are fragrances like and dyes in cosmetics and nickel in jewelry (Kimber 
et al. 2002a; Thyssen et al. 2007).  
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2.1.1 CHEMICAL ALLERGENS  
Most chemical allergens are of low molecular weight (below 500 g/mol) and electrophilic molecules, so-called 
haptens. Due to their small molecular structure haptens are not immunogenic. This implies that the immune 
system fails to recognize the haptens without a stable conjugation to proteins, also known as haptenization. So-
called carrier proteins enables haptens to trigger the immune response. Till now researchers were not able to 
identify or describe a specific protein or protein family as carrier proteins for chemical allergens, but 
nevertheless it was shown that proteins with nucleophilic moieties of amino acids like lysine, histidine and 
cysteine serve as main reaction partners (Ahlfors et al. 2003; Divkovic et al. 2005; Dupuis and Benezra 1982; 
Landsteiner and Jacobs 1936; Lepoittevin et al. 1998; Smith and Hotchkiss 2001; Weltzien et al. 1996). Thus 
the event of haptenization can occur with any protein in the skin (Rock and Goldberg 1999; Smith-Pease 2003). 
With the inherent electrophilic property of haptens they are able to react with the nucleophilic residues of 
cysteine, lysine or histidne (Roberts and Lepoittevin 1998), although some others, known as pre- and pro-
haptens, require previous activation (Dupuis and Benezra 1982; Smith and Hotchkiss 2001). Pre-haptens can 
acquire protein reactivity by auotoxidation (Hagvall et al. 2007; Lepoittevin 2006). For instance, a prominent 
pre-hapten is para-phenylenediamine, used in hair dye products e.g. as ingredient of the so-called black henna 
(Ho et al. 2004; McFadden et al. 2007). Pro-haptens can be converted into reactive molecules by skin enzymes 
such as cyotchrome P450 enzymes or flavin-dependent monooxygenases (Bergstrom et al. 2007; Hagvall et al. 
2007; Karlberg et al. 2007; Smith and Hotchkiss 2001). Some representatitves of pro-haptens are cinnamic 
alcohol, geraniol and 4 allyl-anisol, all used as fragrances in cosmetics (Jaeckh et al. 2012; Schnuch et al. 2004; 
Schnuch et al. 2007).  
Haptens form a large spectrum of different substance classes such as aldehydes, anhydrides, thiazoles, ethers, 
esters, and metal salts and many others. A classification of sensitizers according their electrophilic reactivity 
mechanism was suggested (Roberts et al. 2007c). Roberts and co-workers classified a range of known haptens 
according to their reaction mechanism shown in Table 1. Chemical sensitizers are able to react with nucleophilic 
molecules via Michael reaction, nucleophilic (aromatic) substitutions (SN2 or SNAR), Schiff base reactions and 
acetylation. Metal allergens such as nickel and copper form coordination bonds instead of covalent bonds. Such 
complexations of metals occur e.g. with histidine rich proteins (Thierse et al. 2004). It was shown that 
sensitizing potential of chemicals can be predicted using their reactivity scheme (Patlewicz et al. 2008).  
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Table 1: Reaction mechanism involved in skin sensitization 
The table shows simplified reaction mechanism for Michael acceptors, SNAr electrophile, SN2 electrophiles, Schiff base 
formers and acylating agents with protein nucelophiles (Aptula et al. 2006) 
Mechanistic 
domain 
Protein binding reaction Modified protein Identification 
characteristics 
Michael 
acceptors 
 
Double or triple bond 
with electron 
withdrawing 
substituent X such as  
–CHO, -COR, -CO2R,  
-CN, -SO2R, -NO2 
SNAr 
electrophiles 
 
X = (pseudo) halogen,  
Y’s = electron 
withdrawing groups 
like  
-NO2, -CN, -CHO 
SN2 
electrophiles 
 
X = halogen or leaving 
group bonded to 
primary alkyl, benzylic 
or allylic carbon 
Schiff’ base 
formers 
  
Reactive carbonyl 
compounds such as 
aliphatic aldehydes, 
some α,β or α,γ 
diketones, -ketoester 
Acylating 
agents 
 
X = halogen or leaving 
group (-OC6H5 such 
that XH is acidic 
enough for X- to act as 
good leaving group 
 
2.1.2 PHASES OF ACD: SKIN SENSITIZATION AND ELICITATION 
ACD can be described in the two phases: 1) sensitization phase, corresponding to the symptom-free 
development of ACD, and 2) elicitation phase, which is the symptomatic appearance of ACD (Saint-Mezard et 
al. 2004). The adverse outcome pathway (AOP), key events and consecutive processes involved in the 
mechanism and mode of toxic action, of skin sensitization is complex and involves different cell types, cellular 
responses and vice versa results in activation of cells in the skin (Fig. 1) (OECD 2012). The skin is the largest 
organ and represent a barrier to the environment (Janeway; Efferth; Marquardt, Meyer et al., 2007). Three layers 
of different tissue build the skin, namely: epidermis, dermis and cutis, whereas the epidermis is the import part 
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of the skin in the sensitization process. The epidermis represents the outer layer of the skin and functions as 
protector against harmful environmental effects, microorganism and other influences but also it has an important 
role in immunology (Meyer et al., 2007). Keratinocytes (KC) are the main cell type in the epidermis with a 
frequency of 95%, next to Merkel cells, melanocytes and Langerhans’ cells (LC), the latter are dendritic cells 
(Marquardt). If a hapten penetrates through the stratum corneum, the outer layer of the epidermis and main 
physical penetration barrier, it reaches the layer within the epidermis where it reacts with proteins to form stable 
conjugates, the complete allergen (Dupuis and Benezra 1982; Landsteiner and Jacobs 1936; Weltzien et al. 
1996). If the hapten is not inherently reactive it can be converted to reactive species by autoxidation or 
enzymatic conversion of enzymes mainly from KC (Bergstrom et al. 2007; Svensson 2008). KC can be 
activated by the presence of hapten-protein-conjugates. Activated KC release danger signals in form of 
cytokines like interleukin (IL)-1α and tumor necrosis factor α (TNFα) and facilitates the activation of immature 
dendritic cells (iDC) and hence the inflammatory response. (Kim et al. 2009; Kimber and Cumberbatch 1992). 
iDC are antigen presenting cells (APC) of the skin and more specifically called LC if found in the epidermis. 
Upon recognition and up-take of hapten-protein conjugates iDCs become activated (Aiba et al. 1997). Whilst 
DC undergo a process of maturation, the hapten-protein conjugate is degraded and its fragments are presented 
on the cell surfaces via major histocompatibility complex (MHC) class I and II (Macatonia et al. 1987). Down-
regulation of adhesion molecules such as E-cadherin allow DCs to detach from surrounding tissue 
(Schwarzenberger and Udey 1996). By means of caspase-1 (Antonopoulos et al. 2001) and matrix 
metalloproteinases to penetrate cell-cell contacts of the tissue (Ratzinger et al. 2002), an interplay of cytokines 
(Antonopoulos et al. 2008; Cumberbatch et al. 2001) and the simultaneous down-regulation of C-C chemokine 
receptor type (CCR)2 for skin homing and up-regulation of CCR7 for lymph node homing, DCs migrate out of 
the skin towards the local lymph node where they encounter naïve T cells (Ohl et al. 2004; Sallusto et al. 1998). 
Mature DCs carry cell surface proteins such as CD40, CD80 and CD86, all three so-called maturation markers, 
to facilitate the cell-cell interactions with T cells in addition to antigen-MHC molecules (Kimber and 
Cumberbatch 1992; Hulette et al. 2002; Steinman 2001; Weltzien et al. 1996). If a T cell carries the antigen 
matching T cell receptor (TCR) its activation, differentiation and proliferation into antigen specific T cells takes 
place (Banchereau and Steinman 1998; Weltzien et al. 1996). Development of skin sensitization may require 
several days, from first contact to T cell activation. (Banchereau et al. 2000; Kimber and Cumberbatch 1992; 
Roychowdhury and Svensson 2005; Ryan et al. 2007; Toebak et al. 2009)  
Upon completion of the sensitization phase, specific T cells circulate in the blood stream until the following 
allergen contact. In the event of such a subsequent contact with the allergen the process is similar to the 
sensitization with haptenization, stimulation of KCs to release cytokines, and activation of DCs. Specific T cells 
infiltrate the site of allergen contact and interaction of DC and T cells triggers elicitation of ACD with the 
characteristic symptoms of rash or skin lesions, itchiness, ooze or drain and appearance of blisters, 
desquamation or redness of the skin appear caused by proliferation of KC, vasodilatation and edema 
(Banchereau and Steinman 1998; Pezutto et al. 2006).  
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Figure 1: Process of sensitization and elicitation 
Skin sensitization includes the steps of (1) penetration of the hapten through the skin, (2) activation of not inherently 
reactive haptens by enzymes, (3) protein reaction and uptake of the hapten-protein conjugate, (4) DC activation with 
maturation and migration of DC to the local lymph node, and finally (5) antigen presentation to and activation of naïve T 
cells. Elicitation occurs after subsequent contact with the allergen and the entailed (6) infiltration of specific T cells into site 
of allergen contact triggering the inflammatory reaction. Modified according Banchereau et al. 2000, Kimber and 
Cumberbatch 1992, Roychowdhury et al. 2005 and Ryan et al. 2007, Bauch 2009. 
 
2.2 IDENTIFICATION OF SKIN SENSITIZERS 
2.2.1 LEGAL BACKGROUND IN SKIN SENSITIZATION  
The regulatory bodies, such as US Environmental Protection Agency, US Food and Drug Administration, 
European Chemical Agency or Organization for Economic Co-operation and Development (OECD), demand 
hazard and hazard potency assessment with the current standard methods namely the guinea pig maximization 
test (GPMT) and the murine local lymph node assay (LLNA). Both assays are implemented in OECD testing 
guidelines (OECD TG 406 1992; OECD TG 429 2010) issued by the OECD. There is an increasing interest in 
animal welfare and a demand by public and legal bodies to replace animal testing in general, and especially to 
replace LLNA and GPMT as skin sensitization tests with animal-free test methods. This is also stimulated by 7th 
amendment (2003/15/EC 2003) of the Cosmetic Directive (76/768/EEC 1976), now Cosmetic Regulation (EU 
1223/2009 2009) and the regulation for the registration, evaluation, authorization and restriction of chemicals 
(REACH), a regulation by the European Union. Hence, over the last years, animal-free testing methods for 
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industrial chemicals, pharmaceuticals, cosmetics and agrochemicals became a high priority. The European 
Commission banned the use of animal experiments in 1986 only if scientifically approved alternatives were 
available (European Commisson 1986), whereas the 7th amendment of the Cosmetic Directive implemented a 
testing ban for cosmetic products and ingredients on animals and the marketing of such animal-tested products 
in 2009, except of some the endpoints for repeated-dose toxicity, reproductive toxicity and toxicokinetics 
coming into force in 2013, like skin sensitization. 
2.2.2 STANDARD SKIN SENSITIZATION TEST METHODS 
2.2.2.1 GUINEA PIG TESTS 
So far, the skin sensitizing potential of industrial chemicals, cosmetic ingredients, and agrochemicals has been 
identified through animal testing. Guinea pigs and mice serve as standard animal models and both methods were 
outlined testing guidelines published by the OECD. The protocols of the guinea pigs were set in the OECD 
guideline no. 406 in 1981 and was revised in 1992 (OECD TG 406 1992). The guinea pigs can be treated in two 
different ways. The substance is dissolved in Freund’s complete adjuvant/water or physiological saline and is 
either intradermal injected or applied on the skin, followed by a resting phase of 10 to 14 days to allow the 
development of the immune response. The highest dose should only cause a mild to moderate skin irritation. 
The animals are challenged with another, non-irritating dose, and the extent and degree of the skin reaction is 
assessed in comparison to control animals. The test requires 10 to 20 animals per dosage and 5 to 10 animals per 
control group (OECD TG 406 1992). Two varieties of the guinea pig test are in use which differ in the use of 
adjuvant and the duration of the assay. The maximization test (GPMT) by Magnusson and Kligman is 
performed using Freund’s complete adjuvant, mineral oil solution, and needs 24 days in total (Magnusson and 
Kligman 1969). The second version is the so-called Buehler test (Buehler 1965), a non-adjuvant guinea pig test. 
Assay duration is 32 days. The guinea pig tests cover of sensitization and elicitation phase, but the results rely 
on subjective readout skin reactions. And the limitation to hazard potential only (binary (yes/no) answer) with a 
lack of potency information (Mehling et al. 2012; OECD TG 406 1992).  
2.2.2.2 LOCAL LYMPH NODE ASSAY 
The LLNA procedure, outlined in the OCED guideline 429 in 2002 and revised in 2010 (OECD TG 429 2010) 
was developed by Kimber and co-workers (Kimber et al. 1989). For substance treatment chemicals are 
dissolved in solvents like acetone:olive oil (4:1), N,N-dimethylformamide, propylene glycol, methyl ethyl 
ketone or dimethyl sulfoxide. The maximum applied dose should be 100 % of liquid substances and maximum 
soluble concentrations for solid substances. Substance treatment is carried out by topical application on the 
dorsum of each ear per mouse and treatment group on three consecutive days (see Fig. 2). After a resting phase 
of two days mice are injected with 3H-methyl thymidine and the local lymph nodes of each ear are excised after 
additional 5 hours of incubation. The lymph node cells are isolated and the 3H decay from labeled thymidine is 
evaluated and indicates cell proliferation of lymph node cells. Stimulation indices (SI) are calculated and 
compared to control animals. SI of >3 indicate a test substance as skin sensitizer. According to the 3R concenpt 
(see chapter 2.3) the LLNA represents an alternative method to the GPMT, although it is still an in vivo assay 
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(OECD TG 429 2010). However, fewer number of animals are required (a total of 20 to 25 mice) and less harm 
is caused to animals compared to the GPMT, without a challenge phase and adjuvant. With the quantitative 
assessment of the cellular response of the immune system the LLNA results in objective and quantifiable 
readouts. Compared to human data, the LLNA provides some false positive predictions of substances and this 
has been discussed as one of its disadvantages (Basketter et al. 2009; Garcia et al. 2010; Kreiling et al. 2008; 
Penninks 2006) and the use of radioactive thymidine and consequent increased safety precautions are additional 
disadvantages. Since 2003 the LLNA is used for the assessment of skin sensitizing potency (Kimber et al. 
2003). According to the test substance concentration which induces an SI >3 the substance is classified as 
extreme (<0.1 %), strong (from ≥0.1 % to <1 %), moderate (from ≥1 % to <10 %) and weak (from ≥10 % to 
<100 %). The LLNA was further optimized to reduce the number of animals and is implemented as the so-
called reduced LLNA in the LLNA testing guideline (OECD TG 429 2010). Up to 40 % less animals are used 
compared to the traditional LLNA but forfeit the advantage of potency prediction as with less dose groups no 
dose-response can be assessed (Anderson 2011; OECD TG 429 2010). A non-radioactive protocol was 
published by replacing the 3H-methyl thymidine with 5-bromo-2-deoxyuridine (BrdU) and a colorimetric 
readout of BrdU after cell lysation (Anderson 2011; Kolle et al. 2012a; Kolle et al. 2012b; OECD TG 429 
2010). A list of reference substances to approve sufficient accuracy and reliability according the specified test 
purposes was described (Casati 2007) and a selection of 22 chemicals was published by the Interagency 
Coordinating Committee on the Validation of Alternative Methods (ICCVAM, USA) (Kolle et al. 2012b).  
 
Figure 2: Procedure of LLNA (adopted from (OECD TG 429 2010))  
Mice are treated on the dorsum of the ears with test substance on three consecutive days. After a resting phase of two days, 
mice are injected with 3H-methyl thymidine. After five hours local lymph nodes of the ears are excised and 3H decay is 
assessed to evaluate cell proliferation. 
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2.3 ALTERNATIVE METHODS TO PREDICT SKIN SENSITIZING POTENTIAL 
A guiding principle for alternative methods was described in 1959 by the scientists Russel and Burch, in which 
they described the Reduction, Refinement and Replacement (3R) of animals and animal based test methods, 
known as the 3R concept (Russell and Burch 1959). As mentioned above there is high interest by public and 
regulatory bodies in replacing the LLNA and GPMT with alternative, animal-free test methods (2003/15/EC 
2003; Mehling et al. 2012). Currently, for skin sensitization there is no regulatory acceptance of an animal-free 
method such as an available OECD test guideline or an endorsement by European Center for Validation of 
Alternative Methods (ECVAM, Italy), the Interagency Coordinating Committee on the Validation of Alternative 
Methods (ICCVAM, USA), the National Center for the Replacement, Refinement and Reduction of Animals in 
Research (NC3R, United Kingdom), Netherlands Centre for Alternatives to Animal Use (NCA, Netherlands) 
and the Centre for the Documentation and Evaluation of Alternatives to Animal Experiments (ZEBET, 
Germany),  
The development of assays to replace the current in vivo sensitization tests is a challenge due to the biological 
complexity of cellular processes involved in skin sensitization. To be able to assess skin sensitization in vitro 
the process has to be broken down into single steps and assessed by several methods and adequate and useful 
models, especially to simulate cell response, have to be identified. In case of cells it needs to be considered that 
they are fully functional in their physiological, cellular environment (Matzinger 2007; Matzinger and Kamala 
2011) and that isolation of cells may result in loss and/or altered functions and responses, although some 
functions may still exist (Matzinger 2007; Matzinger and Kamala 2011). Results can be combined in integrated 
testing strategies to cover the full process of skin sensitization (Jaworska et al. 2011; Jowsey et al. 2006; 
Mehling et al. 2012). In the following chapter the most prominent and important steps and corresponding 
animal-free assays for skin sensitization as well as combined test strategies are described. 
2.3.1 IN SILICO METHODS  
As described in the section “chemical allergens” no specific substance class has been defined as the main cause 
of skin sensitization, but according to chemical structure and electrophilic properties skin sensitizing potential of 
test substances can be predicted with the help of algorithms (Patlewicz et al. 2003; Roberts et al. 2007a). The 
Roberts assignment (Tabel. 1), described by Roberts and co-workers (Aptula and Roberts 2006; Roberts et al. 
2007b; Roberts et al. 2007c), was successfully applied on 210 substances by Patlewicz and co-workers 
(Patlewicz et al. 2008). They demonstrated that with consideration of mechanistic applicability domains skin 
sensitizing potential can be predicted. Computer based analysis of molecule structures and experimental data of 
similar or related structures allows the performance of quantitative structure activity relationships (QSAR). The 
most relevant in silico tools for skin sensitization are the OECD QSAR toolbox (Devillers and Mombelli 2010), 
Deductive Estimation of Risk from Existing Knowledge (DEREK) (Barratt and Langowski 1999), TIssue 
MEtabolism Simulator for Skin Sensitization (TIMES-SS) (Patlewicz et al. 2007), computer assisted Evaluation 
of industrial chemical Substances According to Regulation (CAESAR), MCASE and TOP-KAT (Chaudhry et 
al. 2010; Dimitrov et al. 2005; Mehling et al. 2012; Roberts et al. 2007a). None of these test systems has ran 
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through a formal validation, but have been used for screening purposes (Mehling et al. 2012). They can be 
knowledge based (DEREK), rule based (MCASE and CEASAR), non-rule based (TOP-KAT) or creating 
relationships between structure toxicity and structure metabolism (TIMES-SS). OECD published a guideline in 
2007 in order to verify and to ensure reliability of QSAR test systems (OECD 2007). With the help of in silico 
prediction, structural alerts as well as physico-chemical properties like lipophilicity, expressed as octanol/water 
partition coefficient, or the bioavailability in the skin can be obtained (Aeby et al. 2010; Kasting et al. 2008; 
Roberts and Williams 1982). Additionally modules for theoretical metabolic transformation can be included and 
allow a prediction of potential pro-haptens and metabolic products, although false positive predictions for non-
sensitizing chemicals may be increased. The more comprehensive the data base, the higher the accuracy. 
Prediction of the sensitizing potential for chemicals with more than one possible reaction mechanism, e.g. 
aldehydes, proved to be difficult (Franot et al. 1994). The reliability and accuracy of such in silico models are 
dependent on the amount and quality of data used to build up the data base.  
2.3.2 IN CHEMICO METHODS 
Reaction between chemical and protein resulting in the formation of stable protein conjugates is an important 
step in skin sensitization (Landsteiner and Jacobs 1936). Cell free analysis of skin sensitizing potential can be 
performed using peptides or proteins in so-called in chemico methods. With those the skin sensitizing potential 
according the protein reactivity of chemicals can be predicted (Gerberick et al. 2008; Gerberick et al. 2007). 
The most promising in chemico assay is the so-called direct peptide reactivity assay (DPRA) described by 
Gerberick and co-workers in 2004 (Gerberick et al. 2004), and is currently undergoing and has nearly competed 
formal validation at ECVAM (Mehling et al. 2012). The test substance is incubated with two artificial peptides, 
each with an active core containing either one lysine or cysteine residues as nucleophils. The reaction of 
substance with either peptide is measured as the depletion of the individual peptide by high pressure liquid 
chromatography with ultra-violet light absorbance detection (HPLC-UV). Reaction of chemicals with peptides 
result in a shift of the retention time of the respective peptide consequential reducing the peak of the unbound 
peptide. The areas under the curve of treated peptides and control peptides are evaluated and compared to 
estimate the amount of conjugated peptide. In 2007 a decision tree was published in which peptide depletion 
was set in correlation with the potency of skin sensitizers (Gerberick et al. 2007). Gerberick and co-workers 
evaluated the cysteine and lysine dependent peptide depletion as well as the calculated mean of both peptides. 
They were able to describe thresholds to classify the sensitizing potency of chemicals according the mean 
peptide depletion. A chemical is rated with minimal reactivity if the calculated mean peptide depletion of lysine 
and cysteine peptide is smaller than 6.376 % and of low, moderate or high reactivity if the mean peptide 
depletion is >6.376 but <22.62; >22.62 but <42.47 or >42.47, respectively. Although the DPRA showed good 
correlation with the skin sensitization data, prediction of chemicals requiring previous metabolic activation 
cannot be relied on as long as the DPRA does not include a metabolizing system (Gerberick et al. 2009; 
Gerberick et al. 2007). To address this Gerberick and co-workers optimized the DPRA by including a 
peroxide/peroxidase system and showed a reliable prediction of pro-haptens (Gerberick et al. 2009). This 
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improved assays is known as the peroxidase peptide reactivity assay (Gerberick et al. 2009; Troutman et al. 
2011).  
Moreover, Natsch and co-workers established a liquid chromatography-mass spectrometry (LC-MS) based 
detection using a cysteine rich peptide called Cor1 to detect oxidation of the peptide leading to dimerization via 
disulfide bonds caused by chemicals and adduct formation between peptide and chemical (Natsch and Gfeller 
2008). A prominent example is sodium dodecyl sulfate (SDS). It was shown that SDS caused peptide 
dimerization and was rated as sensitizer. Accordingly the optimized DPRA with LC-MS analyses increased the 
predictivity of the peptide depletion by detection of dimerized peptides and is thus able to exclude false positive 
predicted substances. Further peptide reactivity assays have been published by Aleksic and co-workers, who 
used several nucleophilic peptides and LC-MS-MS analysis and were able to obtain qualitative and quantitative 
data as well as results for cysteine dimerisation (Aleksic et al. 2008). Schultz and co-workers used GSH in a 
spectrophotometric assay instead of artificial peptides to predict the protein- or peptide reactive potential of 
chemicals (Schultz et al. 2005). Glutathione (GSH) is a tripeptide consisting of glutamic acid, glycine and 
cysteine and is omnipresent in cells. GSH has an antioxidative role, especially during oxidative stress and 
represents a physiological peptide model compared to artificial peptides. This approach was further applied to 
study the kinetics of haptenization (Böhme et al. 2009; Roberts et al. 2010). Jeong and co-workers published 
recently a modified version of the DPRA in which HPLC-UV analysis of unbound peptides was replaced with a 
colorimetric or fluorescent analysis. After incubation with chemicals the peptides are treated with either amine 
or thiol reactive agent, which only binds to non-conjugated peptides and indicates whether the chemical was 
able to bind to the peptide. Although this method does not reach the predictivities of the DPRA yet, it offers a 
high-throughput method and is independent of HPLC devices (Jeong et al. 2012).  
2.3.3 IN VITRO METHODS 
After the formation of complete antigens (the complexes between haptens and peptides or proteins) cellular 
responses in the skin are required for an immune response (Kimber et al. 2002a; Kimber et al. 2002b; Kimber 
and Dearman 2002) 
2.3.3.1 KERATINOCYTE RESPONSE 
As the main cell type in the epidermis, KCs elaborate inflammatory responses and thus facilitate the activation 
of DC via the release of cytokines like IL-1α or IL-18 (Antonopoulos et al. 2008; Cumberbatch et al. 2001; Van 
Och et al. 2005). KC are metabolically capable cells and are the main activator of pro-haptens into protein 
reactive metabolites (Bergstrom et al. 2007; Jaeckh et al. 2011; Oesch et al. 2007; Reilly et al. 2000; Rolsted et 
al. 2007; Roychowdhury and Svensson 2005; Svensson 2008), in addition to this it was shown that the presence 
of pro-haptens induce levels of CYP1A1 mRNA in KC and thus increased the level of this enzyme, a 
monooxygenase of the cytochrome P450 familiy and transforms its substrate into epoxides (Al Masaoudi et al. 
2001; Oesch et al. 2007). In vitro assays based on human or murine KC cell lines, like HaCaT, NCTC2544 or 
HEL-30, have been used to detect cytokine release (Corsini et al. 1998; Corsini et al. 1999; Corsini et al. 2009; 
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Galbiati et al. 2011; Van Och et al. 2005) or intracellular pathways (Natsch and Emter 2008) in response to 
sensitizers. Treatment of KC with skin sensitizer showed a dose dependent increase of released IL-1α and/or IL-
18 whereas irritants, such as salicylic acid, lactic acid and SDS, did not induce cytokine release (Corsini et al. 
2009; Van Och et al. 2005). The signaling pathway known as Kelch-like ECH associated protein-1 -Nuclear 
factor (erythroid derived 2)like 2 (Keap1-Nrf2) pathway was shown to be one of the signaling pathways 
involved in skin sensitization and was highly investigated in the last years (McKim et al. 2010; Natsch and 
Emter 2008). The Keap1-Nrf2-pathway is described as a cellular sensor for oxidative stress as well as 
electrophilic substances (Dinkova-Kostova et al. 2005; Wakabayashi et al. 2004; Wang and Jaiswal 2006). In 
unstressed cells the transcription factor Nrf2 is bound to the protein Keap1 and thus not able to translocate into 
the nucleus. In addition, if bound to Keap1, Nrf2 will be degraded after ubiquitinylation. Oxidative stress and 
consequential reactive oxygen species (ROS) and/or electrophilic chemicals activate proteins such as protein 
kinase C which phosphorylates Nrf2 and cysteine reactive electrophiles bind to free cysteine residues of Keap1. 
In consequence of the phosphorylation of Nrf2 and changes to Keap1 conformational changes of proteins occurs 
which triggers the dislocation of Keap1 and the translocation of Nrf2 into the nucleus. Nrf2 binds to antioxidant 
response elements (ARE) and regulates gene expression of so-called Phase 2 enzymes like epoxide hydrolase, 
quinine reductase 1 and glutathione s transferase under the control of ARE. The up-regulation of those enzymes 
counteract ROS and triggers the reduction of electrophiles (Dinkova-Kostova et al. 2005; Wakabayashi et al. 
2004; Wang and Jaiswal 2006). A correlation between the activation of Keap1-Nrf2-ARE and the treatment 
with skin sensitizers was shown and reporter gene cell lines to monitor Keap1-Nrf2 pathway activation were 
created (Ellis et al. 2009; Emter et al. 2010; Natsch and Emter 2008). Keratinocyte reporter gene cell lines, 
KeratinoSens and LuSens, both carrying plasmids with an ARE element of the human aldoketo reductase gene 
AKR1C2 (KeratinoSens) or the rat NADPH:quinone oxidoreductase 1 gene (LuSens) followed by a reporter 
gene encoding luciferase (Bauch et al. 2012; Emter et al. 2010). Although a good correlation of sensitizers with 
the activation of Keap1-Nrf2 pathway was found, some sensitizers fail to activate Nrf2 regulated gene 
expression and activate different pathways instead. A prominent example is nickel, which was described by Ade 
and co-workers to activate NFκB signaling but not Nrf2. Nickel forms to coordinative bonds only and is thus 
not able to form the required covalent bonds to cysteine (Ade et al. 2007).  
2.3.3.2 DENDRITIC CELL ACTIVATION 
iDC patrol and screen the skin for foreign molecules (Banchereau and Steinman 1998; Ryan et al. 2007; 
Steinman 1991; Steinman 2001). As APC they are able to recognize, process and present those molecules on 
their cell surface mainly to T cells. APC of the epidermis are called LC and DC in other tissues (Toebak et al. 
2009). DC respond to changes in their environment and are able to detect foreign, exogenous molecules like as 
bacterial structures, such as lipopolysaccharide or glycoproteins, or proteins like ovalbumin and chemicals 
(Aiba et al. 1997; Cella et al. 1997; Hulette et al. 2002 Ryan et al. 2007; Steinman 1991). The process of 
antigen recognition and DC activation is complex and several parameters are involved and some aspects are still 
unknown. It has not been identified, yet, how DCs recognize hapten and/or hapten-protein conjugates. A 
common target, such as a receptor, might be unlikely due to the variety in chemicals structures and the 
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unspecific electrophilic reactions of the haptens with a variety of proteins (OECD 2012). Different theories 
described how dendritic cell may take up haptens. DC possess endocytically activity (Steinman 2001) and are 
able to take up hapten-protein conjugate and to process them (Banchereau and Steinman 1998; Steinman 2001). 
The uptake may happen non-specifically via endocytosis or via internalization of changed cell surface proteins 
and in addition it was shown that haptens or hapten-protein conjugates trigger different signaling pathways (Ade 
et al. 2007; Neves et al. 2011; OECD 2012). Moreover, active transport or passive diffusion through the 
membrane may take place (Smith and Hotchkiss 2001; Smith-Pease 2003) and it was shown that several toll like 
receptors (TLR), P2X7-dependent inflammasome, ROS and the degradation of extracellular matrix seem to play 
a role during the process of recognition and uptake of chemicals allergens, but interactions vary for different 
chemicals (Martin et al. 2008; Schmidt et al. 2010; Weber et al. 2010).  
Nevertheless, DC recognize allergens in their environment, leading to their activation and maturation (Ryan et 
al. 2007). Mature DC migrate out of the epidermis towards the local lymph node (Larsen et al. 1990). They 
encounter T cells and present the antigen on their cell surface (Kimber et al. 2002a; Macatonia et al. 1987). The 
expression of several maturation markers and the release of cytokines are generally correlated with treatment of 
sensitizing chemicals (Aiba et al. 1997; Ozawa et al. 1996; Rambukkana et al. 1995). It was shown that DC 
release cytokines like IL-1β or TNFα, and express cell surface proteins like CD86, CD80, CD54 and CD40 (Enk 
and Katz 1992; Hulette et al. 2002 Ozawa et al. 1996; Pichowski et al. 2000; Tuschl et al. 2000; Tuschl and 
Kovac 2001; Verrier et al. 1999). CD40, CD80 and CD86, so called co-stimulatory molecules, bind to their 
counterparts CD40L or CD28 (ligand for CD80 and CD86) on T cells. It is assumed that CD86-CD28 
interaction amplifies the activation of T cells by mature DC (Fagnoni et al. 1995) and the CD40-CD40L 
interaction is known to trigger IL-12 release and T cell stimulation (Cella et al. 1996). CD54, an intercellular 
adhesion molecule (ICAM-1), is expressed by endothelial cells and immune cells such as DC, and has an 
important role in cell migration. It was shown that CD54 is up-regulated after exposure of DC to sensitizer 
(Ozawa et al. 1996). 
To simulate the cellular response of skin sensitization in vitro different sources of cells are available. Primary 
DC can be freshly isolated from skin, either human or pig skin. In addition monocytes isolated from peripheral 
or cord blood can be used to differentiate into DC. Different kind of immortalized cell lines are available to 
reflect DC, e.g. THP-1, U-937, MUTZ-3 or KG-1 (Mehling et al. 2012). Primary cells provide a system close to 
the in vivo situation but unfortunately the isolation of DC from skin has been proven to be difficult. Not only is 
the frequency of DC in the skin low with a percentage of 1-3 % of total epidermal cells (Bauer et al. 2000) also 
is the rate of spontaneous maturation triggered by the isolation procedure relatively high (Hanau et al. 1988; 
Peiser et al. 2003; Teunissen et al. 1988). Useful surrogates for epidermal DC have been found using human 
CD14 positive peripheral mononuclear blood cells (Lenz et al. 1993; Reuter et al. 2011; Sallusto and 
Lanzavecchia 1994) and human CD34 positive hematopoietic progenitor cells isolated from cord blood or bone 
marrow (Caux et al. 1997; Hooyberghs et al. 2008; Inaba et al. 1992). Those cells can be differentiated into DC 
using cytokines like IL-4 or granulocyte macrophage colony-stimulating factor. Obtaining a DC like phenotype 
after differentiation those cells can be used instead of epidermal DC for in vitro test systems, although they offer 
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high donor-to-donor variations and the procedures are expensive and time consuming (dos Santos et al. 2009). 
Additionally, the handling of potentially infectious human material might be a limiting factor of use (Mehling et 
al. 2012). Therefore the availability of stable DC-like cell lines such as monocytic cell line THP-1 (Ade et al. 
2009; Ashikaga et al. 2002; Sakaguchi et al. 2006; Yoshida et al. 2003), myeloid cells lines U-937 (Ade et al. 
2009; Python et al. 2007) and MUTZ-3 (Azam et al. 2006; Johansson et al. 2011; Python et al. 2007), the bone 
marrow derived cells KG-1 offered a convenient option for in vitro test systems. Those cell lines have been 
intensively studied in the last years and showed DC like characteristics such as a phenotype, properties like 
endocytosis and maturation after treatment with lipopolysaccharide. In addition cell lines ensure a stable 
maintenance of the cells in culture and as well more stable phenotype compared to primary cells. Upon 
stimulation with microbial endotoxins, such as lipopolysaccharides or glycoproteins, or sensitizing chemicals, 
the above mentioned cell lines showed changes in cell surface markers being characteristic for the process of 
skin sensitization, upregulation of CD86, CD54, CD40 and MHC molecules as well as the release of cytokines 
like IL-1β (Ashikaga et al. 2002; Azam et al. 2006; Enk and Katz 1992; Lepoittevin et al. 1998; Python et al. 
2007; Yoshida et al. 2003). Two methods for cell activation of DC like cells turned out to be promising. The 
human cell line activation test (h-CLAT) and the myeloid U-937 skin sensitization test (MUSST) have been 
submitted for pre-validation at ECVAM. Pre-validation of the h-CLAT is nearly finished (Mehling et al. 2012), 
whereas the MUSST pre-validation was stopped or postponed. The h-CLAT is performed using THP-1 
monocytes and was developed by researchers at the companies KAO and Shiseido (Ashikaga et al. 2006; 
Nukada et al. 2011a; Nukada et al. 2012; Sakaguchi et al. 2006; Sakaguchi et al. 2007). Within this test, THP-1 
cells are exposed to chemicals in various concentrations for 24 h and are analyzed regarding their expression of 
CD86 and CD54 cell surface markers using antibody staining and flow cytometry. If the expression of at least 
one of these markers is increased (> 150 % for CD86 and > 200 % for CD54) compared to control cells, the 
chemical is rated as a skin sensitizer. The h-CLAT was intensively studied to proof reliability and performance 
of the method and to investigate its predictivity (Ashikaga et al. 2010; Nukada et al. 2011a; Nukada et al. 
2011b; Sakaguchi et al. 2006; Sakaguchi et al. 2009; Sakaguchi et al. 2010). The MUSST assay is a similar 
method compared to the h-CLAT. U-937 cells are used as DC like cells and CD86 is analyzed as maturation 
marker. This method was initially developed by Python and co-workers at Procter and Gamble (Python et al. 
2007) and was further established as the so called MUSST by scientists at L´Oréal (Ade et al. 2006). Cells are 
incubated with chemicals for 48 h and then analyzed regarding their CD86 cell surface expression using 
antibody staining and flow cytometry. A substance is rated as skin sensitizer if the expression of CD86 was 
increased compared to control cells. The threshold was set for a fold induction of 1.2, comparable with a 20 % 
increase. Several studies have been conducted to show predictivity, reproducibility and robustness of the 
MUSST (Aeby et al. 2010; Maxwell et al. 2011; Thyssen et al. 2007). The changes in cell surface protein 
expressions are important indicators for activated DC. Nevertheless, gene expression using microarray-based 
technology showed promising results (Hooyberghs et al. 2008; Roggen 2011; Schoeters et al. 2007). In the past 
two microarray based assays have been established, the VITOSENS and the “genomic allergen rapid detection 
test”, GARD assay (Hooyberghs et al. 2008; Johansson et al. 2011; Lambrechts et al. 2011; Lambrechts et al. 
2010b; Lambrechts et al. 2010a). VITOSENS is performed using CD34 positive monocytes derived from 
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human cord blood which is collected straight after birth with permission of the women. In order to substitute 
cord blood derived cell to be independent from donors and to reduce donor-to-donor variability, the assay was 
adopted to use the cell line THP-1 instead. Although THP-1 cells were able to discriminate sensitizer and non-
sensitizer it was shown that THP-1 cells respond to sensitizer with different intracellular cascades than CD34 
positive monocytes. Despite the convenience of the cell line the primary cell model remained as cell type of 
choice (Lambrechts et al. 2009). The second assay is the GARD assay using MUTZ-3 cells as DC surrogates 
(Johansson et al. 2011). Cells were treated for 24 h with the chemicals and the transcriptome or RNA content 
were analyzed and a biomarker signature of 200 genes were identified showing potent ability to discriminate 
sensitizers and non-sensitizer (Johansson et al. 2011).  
Another noteworthy method is a transwell migration assays using MUTZ-3 cells differentiated into Langerhans’ 
cell surrogates. DC are able to migrate along chemokine gradients either into the skin or outwards. With regards 
to exposure to chemical sensitizers activation of DC leads to a shift in their chemokine receptor expression on 
the cell surface and thus a changed response to chemokines (Ouwehand et al. 2010). The idea is to discriminate 
sensitizers and non-sensitizers according the migration DC (dos Santos et al. 2009). Immature DC, or after 
treatment with non-sensitizer, migrate along a skin homing chemokine, e.g. CCL5, whereas mature DC, or after 
exposure to sensitizer, migrate towards CXCL12, a lymph node homing chemokine. This was implemented in 
an in vitro assay using MUTZ-LC and recombinant chemokines. Ouwehand and co-workers showed a 
correlation between DC treated with sensitizer and their characteristic to migrate towards CXCL12 and between 
DC treated with non sensitizer and the migration towards CCL5. In addition, they proved the maturation state of 
DC by analyzing the CD86 expression and the secretion of CXLC8 (Ouwehand et al. 2010).  
2.3.3.3 CO CULTURE AND SKIN MODELS 
The function and activity of cells in single cell cultures may be different from mixed cultures or in their 
physiological environment (Matzinger 2007; Matzinger and Kamala 2011). It was shown that single cell 
cultures provide satisfactory results, but nevertheless failed to predict the sensitizing potential of certain 
substances, especially pro-haptens (Chipinda et al. 2011). The interactions of KC and DC facilitate the response 
and activation of DC, thus co-cultures of both cell types may allow cell-cell interactions to resemble the in vivo 
situation. Such co-cultures could take advantage of the metabolic capacity provided by KC to activate pro-
haptens in order to identify potential pro-haptens (Hennen et al. 2011). Schneider and co-workers have 
combined primary human KC with human monocyte derived DC in the “loose fit co-culture based sensitization 
test (Schreiner et al. 2007). DC are evaluated according their maturation state and the expression of CD86 to 
identify the sensitizing potential of chemicals. A dose-response analysis indicates the potency of the sensitizer. 
In addition a co-culture completely devoid of primary cells was published by Hennen and co-workers (Hennen 
et al. 2011). In their studies it was shown that the combination of the KC cell line HaCaT and the DC cell line 
THP-1 seemed to be promising for the prediction of haptens and pro-haptens. The activity of CYP1 enzymes, 
necessary for metabolic conversion of pro-haptens, was increased in co-culture treated HaCaT cells in the 
presence of pro-haptens, e.g. eugenol (Hennen et al. 2011). In addition co-cultures with reconstructed epidermis 
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and LC (Facy et al. 2004; Facy et al. 2005) or full-thickness skin model with MUTZ-3 cells (Laubach et al. 
2011) have been described. Co-culture systems, regardless if DC are cultured with KC cell lines or skin models, 
provide cell-cell interactions similar to the skin. Culture conditions have to be adapted carefully to not influence 
the growth of one or all cells types and to avoid reduced responsiveness. In addition it has to be monitored and 
proved that DC are not activated during co-culture to avoid false positive results. 
As mentioned above reconstructed human epidermis (RHE), also known as skin models or skin equivalents, are 
available and represent artificial, 3D-structured cultures of KC. Various models are commercially available and 
are used to assess chemicals with respect to skin irritating potential (SkinethicTM, EpidermTM and EpiskinTM) 
(Mehling et al. 2012). Metabolic competence was shown for these skin models (Gibbs et al. 2007; Jaeckh et al. 
2011) and are thus applicable to predict pro-haptens in the above mentioned co-cultures. The available skin 
models are not immunologically competent yet due to lack of APC or immune cells, thus no differentiation 
between sensitizers and irritants can be performed (dos Santos et al. 2011) However, it was shown that cell 
viability and release of cytokine IL-1α is in correlation with the irritating potential of the test substance. With 
the implementation of skin models in so-called two-tiered testing strategies the prediction of the skin sensitizing 
potential using e.g. a DC activation assay, and a potency analysis using the skin models is feasible (dos Santos 
et al. 2011; McKim et al. 2010; Teunis et al. 2012). Another model was described by Uchino and co-workers. 
Here, a 3D co-culture of DC, KC and fibroblasts represents a reconstructed skin model with the help of vitrigel 
collagen as the 3D matrix. Analysis of cell surface markers and cytokines after treatment with several chemicals 
sensitizers could be identified. Thus, not only the advantages of cell-cell-interactions and possible cross talk of 
different cell types is combined in this model but also the immune-competence obtained by DC (Uchino et al. 
2009).  
2.3.3.4 T  CELL ACTIVATION 
Activation of naïve T cells to antigen specific memory cells is the last step in the skin sensitization process 
(Kimber et al. 2002a; Thierse et al. 2004). This step requires the interaction of T cells with mature DC, 
presenting the antigen via MHC class II molecules on their cell surface (Kimber and Cumberbatch 1992). 
Several protocols to mimic T cell activation have been published over the last years (Dai and Streilein 1998; 
Dietz et al. 2010; Guironnet et al. 2000; Krasteva et al. 1996; Moulon et al. 1993; Rougier et al. 2000; 
Rustemeyer et al. 1999) measuring the proliferation of naïve T cells upon allergen treatment. However, these 
protocols are not advanced enough to discuss their implementation in testing strategies (Martin 2012; Mehling 
et al. 2012). The development of T cell based in vitro assays is confronted with challenges. Every individual 
person possesses a pool of naïve T cells, each carrying a specific TCR for one antigen. It was reported that some 
allergens may have more than one TCR counterpart, however in each T cell pool only about 1 % of cells have 
the required specificity for the tested allergen. T cell response in vitro requires always primary source of T cells 
as stable cell lines are usually derived from one clone entailing the lack of TCR variety (Kimber et al. 2011; 
Moon et al. 2007).   
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2.3.4 TEST STRATEGIES  
Integrated testing strategies (ITS) or assay combinations are required if complex in vivo processes like skin 
sensitization have to be simulated by in vitro assays (De Wever et al. 2012; Jowsey et al. 2006). Combination of 
assays allows a reflection of the whole process, albeit performed in independent, complementary assays 
(Basketter and Kimber 2009; Jowsey et al. 2006). In the past several combinations of assays have been 
described in which different steps of skin sensitization have been covered or included. Jowsey and co-workers 
proposed a point system based model which served as basis for the development and combination of following 
test strategies (Jowsey et al. 2006). This model by Jowsey and co-workers describes an example for a so-called 
integrated testing strategy (ITS) to predict not only the skin sensitizing potential (skin sensitizer Yes/No) of 
chemicals but also their potency (classification between weak, moderate, strong and extreme). Five steps were 
included in this strategy: (1) structural alerts, (2) bioavailability, (3) protein reactivity, (4) DC maturation and 
(5) T-cell proliferation (Fig. 3). Each individual test is rated with a score between 0 and 4. The parameters 
structural alert and bioavailability are scored with 2 for a clear structural alert or bioavailability. In any other 
cases or uncertainties a score of 1 is assigned as a zero score would imply the lack of potential to induce 
sensitization. The multiplication of scores results in an index of sensitizing potency (Jowsey et al. 2006). 
According to this proposal several combinations and test strategies have been described. Natsch and co-workers 
described a test battery combining peptide reactivity, induction of ARE-dependent luciferase activity in a cell-
based assay, in silico prediction using TIMES-SS, and calculated octanol/water partition coefficient. The 
predictivity of this test battery was 87 % sensitivity, 81 % specificity and 85 % accuracy for number of 116 test 
chemicals (Natsch et al. 2009). Another approach was published by the US contract research organization 
CeeTox, who are specialized with in vitro screenings of drugs and chemicals. A semi-quantitative method to 
determine sensitizing potency was described and combines glutathione peptide depletion with data from gene 
expression analysis of Keap1/Nrf2/ARE/EpRE, ARNT/AhR/XRE or Nrf1/MTF/MRE pathways regulated genes 
was applied to 67 substances and indicated a sensitivity of 81 % and a specificity of 92 % (McKim et al. 2010). 
A probabilistic approach was proposed as Bayesian network integrated testing strategy (BN ITS) combining in 
silico (several parameters), in chemico (DPRA) and in vitro data (ARE luciferase activity, MUSST and IL-8 
secretion) to estimate skin sensitization hazard (Jaworska et al. 2011). It was concluded that simple 
combinations of test methods connected to a decision tree are unlikely to provide an effective display of the data 
assessment and further that the choice and order of tests are dependent on available information and the 
chemical itself.  
Noteworthy is the concept of Threshold of Toxicological Concern (TTC). This concept can be used if no 
experimental toxicological data are existing but knowledge about chemical structure and exposure limits are 
given. Thresholds can be created to describe negligible risk to human health using statistical analysis of 
toxicological data from different and/or structurally related chemicals and extrapolation of no-effect dose levels 
from underlying animal data (Kroes et al. 2005). According to TTC two additional tiered approaches have been 
published, the dermal sensitization threshold (DST) based on existing LLNA data (Safford 2008; Safford et al. 
2011) and the threshold of sensitization concern based human patch test data (TSC; (Keller et al. 2009)). If TSC 
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shows that estimated human exposure exceeds the TSC a QSAR analysis is suggested. In case of negative 
QSAR results DPRA is suggested and a MUSST or h-CLAT assay should be performed in case of uncertainties 
(Keller et al. 2009). In the work presented here a similar, to the above mentioned, test strategy is described (see 
Chapter 6). Combination of protein reactivity (DPRA), KC activation (KeratinoSens assay) and DC like cell 
activation (MUSST or h-CLAT) is described and showed either high probable prediction of non-sensitizers with 
the combination of DPRA and a reporter gene analysis of ARE related genes, and of sensitizers using the 
MUSST and a high overall accuracy with 94 % by combing all three assays (Bauch et al. 2012). 
  
Figure 3: Integrated testing strategy for skin sensitization (Jowsey et al. 2006) 
A binary score was used for data related to structural alerts (derived, for instance, from DEREK) and skin penetration 
potential. A score of 2 is given if structural alerts were identified unequivocally, or if a clear potential of skin 
bioavailability was identified. In all other cases data would be scored 1. For the three in vitro experimental data sets, values 
between 0 and 4 are assigned based on the relative activity compared to a model compound of known high sensitizing 
potential 
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3 AIM OF THE THESIS  
Animal-free methods to predict the hazard of chemicals such as skin sensitizing potential are becoming a more 
and more important issue due to public interest in animal welfare and demands by legal bodies, such as the 
European Union. The process of skin sensitization comprises several steps which are unlikely to be sufficiently 
reflected in a standalone alternative method implying that several assays have to be developed to rebuild the 
process of sensitization in vitro. Before such assays can be used to test chemicals regarding their safety, the 
validity and reliability of these tests have to be confirmed by formal validation initiated by governments and 
within each laboratory performing these assays.  
The overall purpose of this work was to establish cell based in vitro assays and to validate them in order to use 
them as valid screening test systems. The first part on the validation of several animal-free, cell based assay was 
to be performed at BASF SE toxicology laboratories in Germany and included to show the reliability and 
accuracy of these assays and as well to indicate weak points, such as changes of responsiveness of cells over 
time or limitations of positive or negative control substances. A total of 54 substances were selected with known 
sensitizing potential and available human patch test data and/or LLNA from the literature. Furthermore, after 
successful validation test batteries or test strategies should be described to combine several assays to reflect the 
process of skin sensitization and to increase the validity for the detection of probable skin sensitizers. 
1) Four cell based assays were selected for validation: two DC-like cell activation tests (MUSST and h-
CLAT) with the flow cytometric analysis of proteins on the cell surface, and two tests based on reporter 
gene cell lines indicating activated Nrf2-ARE-signaling pathway with luminescence as readout for 
activated gene expression. In addition cell viability tests were to be performed in parallel using 
propidium iodide staining or the proliferation assay MTT. Additional data from the peptide binding 
assay DPRA and computer based analysis of molecule structures using the OECD toolbox were already 
available and evaluated for purposes of creating a test strategy. 
2) By means of Cooper statistics for each assay the predictivities should be expressed with values for 
sensitivity, specificity and accuracy to be able to directly compare the assays and to identify most 
meaningful assay combinations in order to reflect the process of skin sensitization in its complexity and 
to increase the predictivity compared to single assays.  
Since the first part indicated a high predictive value of those assays which address early protein interactions of 
haptens, the second part further investigated protein reactivity and the interference of antibody binding to 
proteins caused by the haptenization. To gain better insights into the process of haptenization and its 
significance in skin sensitization and compound validation mechanistic studies should be carried out. Therefore, 
the second part of this thesis was performed in the Laboratories of the Toxicology group at the University of 
Manchester in a group specialized on skin sensitization. This work comprised the experimental study of protein 
reactivity of chemicals with proteins on the cell surface and the characterization of interference of these 
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haptenizations with antibody binding to those proteins on the cell surface. Focus was set on the investigation of 
following aspects: 
1) With the model sensitizer 1-chloro-2,4-dinitrobenzene (DNCB) and the model cell surface proteins, 
CD14 and CD54, it should be determined whether treatment of cells with sensitizers results in reduced 
binding of antibodies against those proteins or if chemical treatment leads to reduced levels of 
detectable proteins due to protein internalization. Antibody staining and flow cytometric analyses were 
performed on viable and metabolically inhibited cells to show the influence of cell viability on results. 
2)  To investigate whether proteins with DNCB are internalized or if DNCB is able to permeate through 
the cell membrane, intracellular bound DNCB should be detected after permeabilization of cells with 
saponin and intracellular antibody staining by flow cytometric analysis. 
3) Further it was to be assessed whether additional sensitizers or irritants have the same effects on 
detectable cell surface proteins as DNCB. Therefore para-phenylene diamine, para-benzoquinone, 
oxazolone and formaldehyde were to be used as sensitizers and SDS and salicylic acid as irritants.  
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4 VALIDATION STUDY OF THE KERATINOSENS ASSAY 
4.1 THE INTRA- AND INTER-LABORATORY REPRODUCIBILITY AND PREDICTIVITY OF THE KERATINOSENS 
ASSAY TO PREDICT SKIN SENSITIZERS IN VITRO: RESULTS OF A RING-TRIAL STUDY IN FIVE 
LABORATORIES 
 
Natsch, A; Bauch, C.; Foertsch, L; Gerberick, F; Norman, K; Hilberer, A; Inglis, H; Landsiedel, R; Onken, S; 
Reuter, H; Schepky, A; Emter, R: The intra- and inter-laboratory reproducibility and predictivity of the 
KeratinoSens assay to predict skin sensitizers in vitro: Results of a ring-study in five laboratories. Toxicology 
in vitro 25 (3), p 733-744 2011,   DOI: 10.1016/j.tiv.2010.12.014  
 
The KeratinoSens assay is a reporter gene based analysis to predict skin sensitizing potential of chemicals. The 
cell line used in this assay shares the same name than the assay: KeratinoSens. The cell line was developed by 
Natsch and co-workers (Ellis et al. 2009; Emter et al. 2010; Natsch and Emter 2008). The human keratinocyte 
cell line HaCaT was stably transfected with a plasmid carrying an ARE element of the AKR1C2 gene and a 
reporter gene for the firefly luciferase. The enzymatic activity of luciferase was used for readout. Genes under 
the control of ARE have been shown to be up-regulated if cells were exposed to sensitizer to regulate 
glutathione homeostasis, inhibition of inflammation and the depletion of ROS (Dinkova-Kostova et al. 2005). 
The mediator of ARE activation is the transcription factor Nrf2. In non-stressed cells Nrf2 is inactive as it is 
bound to the protector protein Keap1 and degraded after being ubiquitinylated. Oxidative stress and 
consequential ROS or electrophilic substances, such as skin sensitizers, activate the phosphorylations of Nrf2 by 
kinases such a protein kinase C. the Keap1 protein is rich in free cysteine residues and is thus a potential 
reaction partner of cysteine reactive electrophiles. Conformational changes caused by the phosphorylations of 
Nrf2 and the reaction with cysteine residues of Keap1 leads to the dissociation of Nrf2 and Keap1 and thus 
promotes the translocation of Nrf2 into the nucleus. It was shown that skin sensitizers are able to specifically 
activate the Nrf2-ARE-gene expression (Natsch and Emter 2008; Ryan et al. 2004; Vandebriel et al. 2010) 
although some sensitizer, like nickel, fail to activate it (Ade et al. 2007).  
The ring trial study presented in this manuscript was initiated and led by Givaudan, a fragrance producing 
company in Switzerland. The purpose was to show that the in vitro assay KeratinoSens is transferable and 
reproducible. In addition one intention was to identify critical steps in the standard operating procedure and to 
set quality criteria in order to improve the protocol for a successful submission for formal pre-validation at 
ECVAM.  
Cells were maintained under the presence of the selection marker Geneticin to ensure the propagation of 
reporter gene positive cells. For chemical treatment, the adherent cells were trypsinized and plated in 96 well 
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plates for luminescence analysis or normal cell culture plates for cell viability assay and were allowed to adhere 
for 24 h. Chemicals were dissolved in appropriate solvent and medium and cells were treated for 48 h. Induction 
of the reporter gene was read by measuring the activity of the luciferase via the emitted luminescent signal upon 
addition of coelenterazine. Cytotoxicity caused by tested substances was measured using a proliferation and cell 
viability assay with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, the MTT cell viability 
assay.  
The study comprised two phases. During the first phase the correct performance of the protocol, the stability of 
the cell line and sensitivity of the used luminometer reader of each laboratory were to be proved. The protocol 
was easily adopted in each laboratory although no training was performed. Two hurdles were reported, although 
they were more of technical nature than related to the assay and cell line. Different luminometer readers and 
luciferin substrates led to variations in background levels between the laboratories. Diverse luciferase substrates, 
namely flash-substrates and glow-substrates, exhibited differences in the absolute dose of emitted light. Glow-
substrates are adopted for high-throughput screenings and ensure a steady, long-lived signal, entailing a reduced 
absolute amount of emitted light. Flash substrates to the contrary provide a strong emitted light signal, which 
quickly decreases over time. For the purpose of the ring trial study the flash substrate was selected in order to 
increase the sensitivity of the assay.  
Within the first phase of the ring trial study four sensitizer and three non-sensitizers were tested and proved the 
stable performance of the assay in each laboratory, and that variations between laboratories do not affect the 
prediction. Three of four sensitizers were identified as sensitizers and the dose response curves were 
comparable. All non-sensitizers were reported with negative response, whereas one sensitizing substance 
showed borderline behavior.  
The second phase of the ring trial study comprised a set of 21 blind-coded substances; among which 15 
substances were known skin sensitizer and the other six non-sensitizers. Thus, with the seven substances tested 
in phase 1, each participant tested a total number of 28 substances. The calculations of Cooper statistics 
indicated sensitivities greater than 84 % in all laboratories with the highest sensitivity amounting to 94 %. 
Specificities were 100 % for all laboratories except one (78 %) and the accuracies were greater than 86 %. 
Despite the high predictivity false negative substances were reported.  
Overall, the ring-trial study indicated that the KeratinoSens assay is reliable in its performance and yields high 
predictivity, at least for the limited number of tested substances. The inter-laboratory transfer of the assay and 
the protocol indicated few, technical issues, which were addressed by including a training protocol to ensure 
parameters such as high sensitivity, low variability in controls and exclusion of gradients across the plate 
especially caused by the plate reader used for luminescence measurements. Quality criteria were adjusted and 
the new, updated protocol was submitted for official pre-validation at ECVAM. 
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This validation study was part of my PhD project. The establishment of the assay within our laboratories as well 
as the performance of all the experiments of one participating laboratory (Lab 3) and the data evaluation have 
been solely performed by myself.  
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5 VALIDATION STUDY OF A BATTERY OF FOUR TEST SYSTEMS 
5.1 INTRA-LABORATORY VALIDATION OF FOUR IN VITRO ASSAYS FOR THE PREDICTION OF THE SKIN 
SENSITIZING POTENTIAL OF CHEMICALS 
 
Bauch C.; Kolle S. N.; Fabian E.; Pachel C.; Ramirez, T.; Wiench B.; Wruck, C.J.; van Ravenzwaay, B; 
Landsiedel, R.: Intralaboratory validation of four in vitro assays for the prediction of the skin sensitizing 
potential of chemicals; Toxicology in vitro 25 (6) SI p. 1162-1168; 2011, DOI: 10.1016/j.tiv.2011.05.030  
 
This chapter describes an in-house validation study published in Toxicology In Vitro. The aim of this study was 
the performance of four in vitro assays with 23 chemicals of known sensitizing potential in order to directly 
compare these test systems and to spot differences in their capability to predict chemicals as sensitizers. The test 
chemicals were 2,4,6-trinitrobenzene and the 22 performance standards of the LLNA according the OECD 
guideline 429. Although this list of chemicals represents a small selection, it comprises a variety of non-
sensitizers and sensitizers of various potencies as well as pro- and pre-haptens and metals. Performance of the 
same test substances with different assays allows a direct comparison and shows whether an assay is deficient in 
prediction capacity and if combination of assays into an ITS may compensate such underestimations. The four 
assays chosen for this study were the in chemico prediction of protein reactivity using the DPRA assay, 
activation of the Keap1-Nrf2-signaling pathway using the previous described KeratinoSens assay, and the 
detection of dendritic cell activation using dendritic cell-like cell lines THP-1 in the h-CLAT and U-937 in the 
MUSST.  
The cell-free in chemico assay DPRA (described in Chapter 2.3.2 in chemico assays) was used to assess the 
potential of chemicals to react with peptides and proteins. Therefore both model peptides were incubated 
separately with 100 mM test substance at room temperature for 24 h. The mixture was then analyzed using a 
HPLC-UV, and free, non-reacted peptides were detected at 220 nm. If test a substance formed stable conjugates 
with the peptides the area under the curve was reduced compared to the peak of non-treated peptides, an effect 
called peptide depletion. In this work, a substance was classified as skin sensitizer if the averaged peptide 
depletion of cysteine and lysine peptide was greater than 6.376%, adopted from the decision tree by Gerberick 
and co-workers (Gerberick et al. 2007). The decision tree allows an estimation of the sensitizing potency but 
was neglected due to the lack of such prediction models of KeratinoSens, MUSST and h-CLAT. The results of 
tested chemicals showed that the DPRA predicted 21 out of 23 substances correctly.  
The KeratinoSens assay, performed as described above (see chapter 4), predicted 20 out of 23 substances 
correctly. No substance was predicted as false positive. 
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The DC activation assay h-CLAT measures the activation of the DC like cell line THP-1, a human myeloid cell 
line. The readout is the up-regulation of CD86 and CD54, two cell surface makers of DC known to be up-
regulated during the process of DC maturation. Treatment with test substance was performed over 24 h and cell 
surface expression of CD86 and CD54 were measured using antibody staining and flow cytometric analyses. 
Comparison to untreated cells indicated the changes in expression, and substances were rated as skin sensitizers 
if CD86 expression was greater than 150% and/or CD54 levels were greater than 200%. Results of the h-CLAT 
yielded a correct prediction for 20 out of 23 substances.  
The counterpart to the h-CLAT is the DC activation assay MUSST which reflects the activation of the cell line 
U-937, a human monocytic cell line. Main differences to the h-CLAT, apart from the cell line, are the use of 
only CD86 as maturation marker and the exposure of cells with the substance for 48 h. Chemicals were rated as 
skin sensitizers if the expression of CD86 was greater than a 1.2-fold induction compared to control cells. 
Results of the MUSST showed a correct prediction of 20 out of 23 substances, whereas no false positive 
prediction occurred.  
Calculation of the Cooper statistics compared to human patch test data from literature revealed sensitivities of 
81 % for KeratinoSens, h-CLAT and MUSST and 93 % for DPRA. h-CLAT and DPRA exhibited specificities 
of 86 % and KeratinoSens and MUSST had a 100 % sensitivity. Overall, the validated in vitro assays had an 
accuracy to predict sensitizing potential of chemicals with 83 % (h-CLAT), 87 % (MUSST and KeratinoSens) 
and 91 % (DPRA). As the LLNA is the current prediction model for skin sensitization and is referred to as the 
gold standard, results were compared to literature data from the LLNA. Nickel chloride is predicted as non-
sensitizer and SDS as sensitizer in the LLNA. Including these corrections the Cooper statistics changed to 
sensitivities of 75 % (MUSST), 81 % (KeratinoSens and h-CLAT) and 93 % (DPRA) whereas specificities 
ranged from 86 % (MUSST, h-CLAT, DPRA) and 100 % (KeratinoSens). The overall accuracies to predict 
sensitizing potential of chemicals were 78 % (MUSST), 83 % (h-CLAT), 87% (KeratinoSens) and 91 % 
(DPRA).  
This study showed the successful validation of four different alternative, animal-free methods with the use of 
LLNA performance standards according the OCED guideline 429. The predictivities of each single assay were 
relatively high with accuracies above 83%. A stricter definition of the applicability domain leads to the 
exclusion of certain substances, e.g. pro-haptens and might lead to higher prediction but might also conceal 
some weak points of the assay. 
The validation of KeratinoSens for this work presented was part of my PhD project. Assay performance and 
data evaluations were solely performed by myself. I have contributed to experiments for MUSST and h-CLAT 
performance and overtook the data evaluation of both assays. The data used from the DPRA assay were already 
existing and only data evaluation for this work had to be done. The arrangement of results and writing of the 
manuscript was also my duty.   
42 
 
43 
 
44 
 
45 
 
46 
 
47 
 
48 
 
  
49 
 
6 DEFINITION OF A TEST STRATEGY 
6.1 PUTTING THE PARTS TOGETHER: COMBINING IN VITRO METHODS TO TEST FOR SKIN SENSITIZING 
POTENTIALS 
 
Bauch C.; Kolle S. N.; Ramirez, T.; Eltze, T.; Fabian E.; Mehling, A.; Teubner, W.; van Ravenzwaay, B; 
Landsiedel, R.: Putting the parts together: Combining in vitro methods to test for skin sensitizing potentials.; 
Regulatory Toxicology and Pharmacology 63 (3), p.489-504; DOI: 10.1016/j.yrtph.2012.05.013; 2012 
 
This chapter focuses on the continued validation of the four assays described in the previous chapter (Chapter 
5). With the manuscript “Putting the parts together: Combining in vitro methods to test for skin sensitizing 
potential” an extended study with a total of 54 chemicals are described. In addition to the assays DPRA, 
KeratinoSens, MUSST and h-CLAT a second reporter gene based assay was performed, so-called LuSens assay. 
LuSens is similar to KeratinoSens in its principle and a probable alternative for it. The main difference between 
LuSens and KeratinoSens cell line are the underlying ARE elements of the used genes. LuSens carries the ARE 
element of the rat NADPH:quinine oxidoreductase 1 gene and a puromycin resistance gene as a selection 
marker. The in silico method OECD QSAR Toolbox (Version 2.0 2010) was used for an initial prediction of 
protein reactive properties and for a possible reaction mechanism. The second objective of this study was to 
develop a simple model to combine results of the individual assays of this testing battery in order to reflect the 
steps of the AOP of skin sensitization to achieve a high predictivity of skin sensitization potentials in humans. 
Due to technical issues during this study few test substances had to be excluded from the initial list of 59 test 
substances: 1-chlorobenzene, 1-bromobutan and geraniol, since they precipitated in the cell culture media 
during the performance of MUSST and h-CLAT. The solubility could not be increased as by higher DMSO 
concentrations (>0. 5% of DMSO) activation of DC was recorded. In addition the test substances Tween 80 and 
Triton-X 100 seemed to interfere with the performance of the used flow cytometer. Although cells were washed 
to remove remaining test substance the system detected unspecific air bubbles and created error messages. The 
final list of 54 chemicals represents various chemical classes and with different proposed reaction mechanism. 
Although most chemicals have been described in the literature, reliable human patch test data were only 
available for 50 compounds and LLNA data only for 53, hence calculated prediction could only be performed 
for this number of chemicals.  
The DPRA, KeratinoSens, MUSST and h-CLAT assays were carried out as described in the previous chapter 
and had the following number of correct predictions compared to human data as following: 43, 40, 43 and 38 
out of 50 using DPRA, KeratinoSens, MUSST and h-CLAT, respectively. Compared to LLNA data the number 
of correct predictions was 42, 43, 39 and 39 out of 53 using DPRA, KeratinoSens, MUSST and h-CLAT, 
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respectively. The reporter gene cell line HaCaT NQO1 was prepared in collaboration with Dr. Christopher 
Wruck at RWTH Aachen and was further established as LuSens at BASF SE and was integrated in an assay 
with the same name. The LuSens predicted 42 out of 50 or 41 out of 53 correctly, compared to human data or 
LLNA data respectively.  
For an initial prediction of sensitization potential the OECD QSAR Toolbox was used. The software identifies 
chemical structure elements likely to react with proteins and proposes a possible reaction mechanism. The 
OECD QSAR toolbox can include a metabolism feature to analyze possible metabolites, which could predict 
pro-haptenic substances, albeit this feature was not used in this work. Nevertheless, the OECD QSAR Toolbox 
predicted 40 out of 50 or 37 out of 53 substances correctly if compared to human or LLNA data, respectively.  
Calculation of Cooper statistics if compared to human patch test data (or LLNA data) indicated sensitivities of 
the single assays between 64 % and 89 % (56 % and 83 %) and specificities ranged between 73 % and 100 % 
(71 % and 100 %). Accuracies for the single assays were between 76 % and 86 % (74 % and 81 %.).  
Combination of two assays changed the predictivity for all combinations compared to human data (or LLNA 
data). A substance was rated as sensitizer if at least one of two assays gave a positive result. Thus sensitivities 
have been increased up to a range between 93 % and 100 % (86 % and 94 %,) for various combinations of two 
assays, and specificities decreased down to a range of 56 % to 82 % (53 % to 92 %). 
The most promising combination was obtained with three assays with the application of a two out of three rule. 
A chemical was classified as a probable sensitizer if any two of the selected three assay gave positive results. 
Combination of DPRA, LuSens or KeratinoSens with MUSST resulted in sensitivities of 93 % (81 %), 
specificities of 95 % (88 %) and accuracies of 94 % (83% ) if compared to human data (or LLNA data) 
regardless whether combination with LuSens or KeratinoSens was applied.  
To further describe a testing strategy a selection of assays of this testing battery was performed to represent 
three consecutive early steps of the AOP of skin sensitization. DPRA and LuSens (or KeratinoSens) represent 
haptenization and KC activation. Combination of the results of both assay (potential sensitizer if one assay gives 
a positive result) allows for predictions of non sensitizers with a sensitivity of 100%. This implies that a skin 
sensitization potential can be excluded if there is neither haptenization nor KC and that activation for the 
combination of these two steps appears to be a necessary step of skin sensitization. Likewise, the MUSST 
represents DC activation and resulted in predictions of sensitizers with a specificity of 100%. This implies that 
in many cases DC activation is sufficient to predict skin sensitizing potential.  
In few cases the results of these three assays can be inconclusive (e.g. DPRA or LuSens are positive, but 
MUSST is negative) In such cases a weight of evidence (WoE) is proposed: If any two of these three assays are 
positive the substance is rated as skin sensitizer. The h-CLAT can replace the MUSST equally, although its 
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specificity was compared to MUSST assay only 77%. The figure of the manuscript was updated and is shown in 
Figure 4. 
 
Figure 4. Updated figure of proposed testing strategy (Bauch et al. 2012) 
According to the AOP for skin sensitization was a test strategy postulated using DPRA to predict protein reactivity, Nrf2-
ARE-reporter gene analysis (either LuSens or KeratinoSens) for KC activation and indirect protein reactivity for a high 
probable exclusion of sensitizing potential and the cell activation assays MUSST or h-CLAT to predict DC activation and 
high probable prediction of sensitizing potential. In case of contradicting results a Weight of Evidence is proposed offering 
a high overall accuracy.  
 
The validation of KeratinoSens as well as the establishment and validation of the LuSens cell line were part of 
my PhD project with assay performance and data evaluations and were solely performed by myself. I 
contributed the performance of MUSST and h-CLAT and performed data evaluation. Literature research 
according reaction mechanism and the arrangement of results and writing of the manuscript were also my duty. 
The data used from the DPRA assay were already existing and data evaluation for this work had to be done.  
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7 HAPTENIZATION IN VITRO 
7.1 CHARACTERIZATION OF HAPTENIZATION OF CHEMICAL SENSITIZER ON THE CELL SURFACE  
 
Bauch C.; Dearman R.J.; Kimber I., van Ravenzwaay B.; Landsiedel, R.: Characterization of haptenization of 
chemical sensitizer on the cell surface 
Submitted at Toxicology In Vitro; Submitted on the 03rd of February: (Submission letter see Appendix)  
 
The manuscript “Characterization of haptenization of chemical sensitizer on the cell surface” has been 
submitted and is currently under review. It describes the investigation and characterization of the reaction of 
chemical sensitizers with proteins on the cell surface of two DC like cell lines, U-937 and THP-1, both used in 
the previously described DC activation assays. The model sensitizer 1-chloro-2,4-dinitrobenzene (DNCB) was 
used to investigate whether the treatment of cells leads to a) an interference with antibody binding indicated by 
reduced level of bound antibody or b) removal of conjugated protein from the cell surface by internalization and 
degradation of the conjugated protein. The initial hypothesis was that reaction of chemicals with proteins leads 
to inevitable changes of the antibody binding site and thus to a loss of antibody affinity. Three possible 
interactions with antibody binding can be described (Figure 5): covalent binding of the chemical may block 
antibody recognition (1) directly by changing polarity of hydrophobicity of the epitope, (2) indirectly by 
conformational changes of the entire epitop or (3) sterical hindrance of antibody binding site. 
The selection of the cell surface determinant was accord to the following criteria: 1) either constitutive 
expression of the protein on the cell surface or possibility to control expression levels and 2) availability of 
antibodies for flow cytometric analyses. Both cell lines were reported to express CD14 and CD54 constitutively 
or upon stimulation. Although CD54 is usually quantified to determine activated DC, in this investigation both 
markers were used as model protein to assess reactivity of chemicals with cell surface proteins.  
Experiments with DNCB indicated that a 2 h incubation had a dose dependent effect on detectable levels of both 
markers. Irreversible metabolic inhibition of cells with sodium azide or fixation with formaldehyde abrogated 
these effects, whereas reversible inhibition of endocytosis with on ice treatment shifted the dose response 
towards higher concentrations. Triggering protein turnover with specific antibodies, so called antibody 
modulation, indicated protein uptake under standard conditions at RT but inhibited uptake for on ice and for 
sodium azide treated cells. These findings, especially the controversial findings for on ice treated cells, suggest 
that reduced levels of detected proteins are likely to be a combination of protein uptake and reduced antibody 
binding. In addition it is likely that the process of protein conjugation on the cell surface and the internalization 
of the altered protein is involved in the process of dendritic cell activation.  
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Figure 5: Hypothesis of chemical treatment, blocked antibody recognition and antibody binding. 
Covalent binding of the chemical may (a) change the epitope directly and thus blocks recognition; (b) cause conformational 
changes and alters the epitope or (c) sterically block the antibody binding site.  
 
It was further investigated whether these effects on cell surface proteins are restricted to skin sensitizers and the 
associated protein conjugation or if the presence of any chemical may trigger changes in and uptake of proteins. 
Therefore the sensitizers para-phenylenediamine, oxazolone, para-benzoquinone and formaldehyde were tested. 
The known irritants salicylic acid and SDS were selected as additional substances in order to show that the 
protein reactivity of sensitizers triggers changes in surface protein level but not the presence of a chemical. 
Increasing concentrations of para-phenylenediamine led to a corresponding decrease of the assessed cell surface 
determinant. The tests with oxazolone, para-benzoquinone and formaldehyde showed a decrease of the assessed 
protein expression when applied in lower concentrations and an increase at higher concentrations. For the latter 
effect was rationalized with the up-regulation of the chosen cell surface determinant by activation of DC It was 
assumed that the detectable reaction of chemicals with the protein depends an equilibrium of newly synthesized 
protein and conjugation reaction. As expected, treatment with irritants did not affect the protein detection at 
subtoxic concentrations. Reduced cell viability especially after treatment with SDS lead to a marked reduction 
of the detectable protein not only due to reduced cell number but also being able as detergent to extract protein 
from the cell membrane.  
These results indicate that, although further validation is required, an antibody binding test may be used for 
assessment of chemical sensitizers and their effect on cell surface proteins. However, further work is still 
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needed. For instance the protein determinant could be exchanged for a surface protein that is less responsive to 
DC activation. This may reduce variability of results caused by protein expression due to activation of cells. In 
addition, cell activation could be avoided by investigating cell lines other than DC, that are less responsive to 
sensitizing chemicals. 
The experimental work as well as the data evaluation of this project was solely performed in context of this PhD 
project. None of the experiments were performed by others.  
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7.2 ADDITIONAL WORK ON HAPTENIZATION IN VITRO 
 
On the basis of work shown in chapter 7.1 the hypothesis was made that haptenization of proteins and chemical 
sensitizer lead to reduced antibody binding but also to internalization of the protein on the cell surface. 
Additional work was performed to prove whether antibody affinity to protein is reduced after its conjugation 
with chemicals. The possible mechanisms are proposed and are shown in Fig. 5 in chapter 7.1. Protein 
conjugates were prepared with model proteins and the known chemical sensitizer DNCB and 1-fluoro-2,4-
dinitrobenzene (DNFB).  
Analysis of protein conjugates with an inhibition enzyme linked immunosorbent assay indicated that 
conjugation of proteins with DNFB displaced binding antibody. Conjugates prepared with DNCB required 
DMSO as solvent and did not show any effect on antibody binding. Changes of conditions during conjugate 
preparation did not results in qualitative conjugates.  
Nevertheless this approach showed that the chemical sensitizer DNFB forms stable conjugates with proteins and 
that this conjugation can be detected using antibody directed against the protein. This method was not applicable 
for DNCB and it was presumed that the presence of DMSO somehow interferes with the reaction conditions 
required to form stable conjugates. Nevertheless, the results indicate that chemical conjugation in general can 
interfere with antibody binding. With regards to the results shown in chapter 7.1 it is indicated that chemical 
conjugation with cell surface protein may have an effect on the detection using antibody.  
The manuscript for this work is currently under preparation.  
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8 DISCUSSION 
The purpose of this work was the development, establishment and validation of animal-free test methods to 
address different steps of the AOP of skin sensitization induced by chemicals and to propose a test strategy with 
selected assays to predict the skin sensitizing potential.  
Therefore cell based assays but also in chemico and in silico based methods were established and validated with 
a defined set of substances of known sensitizing potential in humans (See chapter 4, 5 and 6) (Bauch et al. 2011; 
Bauch et al. 2012; Natsch et al. 2011). This first part revealed high predictivities of those methods addressing 
early events of the AOP, i.e. the haptenization. Therefore the second part of this work focused on this event and 
investigated interactions of chemical sensitizers and proteins, using surface proteins of DC like cell lines as a 
model. The aim was to show whether cell surface proteins are the target of chemical sensitizers and if so, if this 
could be detected using a flow cytometry based analysis and the loss or reduction of antibody binding to the 
altered protein (Chapter 7) (Bauch submitted).  
The validation studies of the several assays indicated high accuracies for each single assays (>76%). As 
expected due to the complex biological process of skin sensitization, none of the shown assay exceeded the 
predictive capacity of the LLNA (90 % compared to human data). Combination of assays which reflect three 
different and important steps of the sensitization process according to the AOP, namely protein reactivity 
(DPRA), KC response and indirect protein reactivity (LuSens and/or KeratinoSens) and DC activation 
(MUSST) reached remarkable predictivity of 94 % and thereby exceeded the LLNA for the given selection of 
chemicals. In addition the combination of three assays offered higher accuracies compared to other published 
ITS, although it needs to be considered that the selection of chemicals differed in the number of chemicals and 
also the composition. McKim and co-workers discussed a combination of a glutathione peptide reactivity assay 
with gene expression analysis for Keap1/Nrf2/ARE/EpRE, ARNT/AhR/XRE or Nrf1/MTF/MRE pathways 
regulated genes and showed for 67 tested substances an accuracy of 84 % (McKim et al. 2010), whereas Natsch 
and co-workers described an ITS with peptide reactivity, induction of ARE-dependent luciferase activity in a 
cell-based assay, in silico prediction using TIMES-SS and calculated octanol–water partition coefficient. This 
ITS reached an accuracy of 86 % with a total number of 116 tested substances (Natsch et al. 2009). The ITS 
described in Chapter 6 and shown in Figure 4 offers some advantages. Besides the prediction of the absence or 
presence of a skin sensitization potential, one-sided question can be of higher relevance (e.g. can we exclude a 
skin sensitization potential?). A testing battery offers the possibility to specifically address those questions: 
Combining the peptide reactivity analysis with the KC reporter gene assay gives results were the sensitizing 
potential can be excluded with high probability. Combination of both assays yielded in a high sensitivity 
(100 %). If in addition an assay or combination is selected with a high specificity, the prediction of sensitizing 
potential can be performed with high probability. Within the tested substances the MUSST showed a specificity 
of 100 % and had thus a predictive value for positive results of 100 %. Thus being able to predict or vice versa 
to exclude the sensitizing potentials of chemicals this strategy could be useful for screenings during the early 
process of development of new compounds.  
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Reactions of chemical sensitizers with proteins in the skin constitute one important step in early process of skin 
sensitization Although the necessity of the conjugate formation is known, very little is known about the target 
proteins, which react with the haptens, and their fate. Sensitizers react with amino- and thiol moieties of the 
respective amino acids - like lysine and cysteine – in a protein. Thus any lysine or cysteine containing protein 
may be targets of the chemical reaction. It was discussed that chemical reaction formally reflects post 
translational modification and leads to changes in function, conformation and protein-protein interaction (Martin 
2012; Todd et al. 2010; Walter and Ron 2011). This was described to induce the activation of unfolded protein 
response and following endoplasmatic reticulum stress, such as disrupted protein folding (Todd et al. 2010; 
Walter and Ron 2011). In the work presented here the analysis of cell surface proteins after treatment with 
sensitizers (see chapter 7) indicated a reduced levels of cell surface proteins after treatment with sensitizers. 
Further the results indicated that reduced detectable levels might be a combination of inhibited antibody binding 
and uptake of the changed cell surface determinant. These results correlate with the study of Hirota and co-
workers. They reported reduced levels of free cysteine and lysine residues on the cell surface and a subsequent 
activation of DC after chemical treatment, whereas treatment with already conjugated chemicals did not affect 
the level of free amino acids on the cell surface and failed to trigger DC activation (Hirota et al. 2009). Again 
this may indicate that the conjugation of proteins on the cell surface of DC and subsequent internalization is an 
important trigger to activate DC. 
The development of alternatives to animal experiments is challenging as complex processes, which may affect 
each other, have to be simulated in vitro. Moreover several technical hurdles had to be overcome during the 
validation studies and the development of the cell based method. The concentrations of solvents like DMSO, 
especially in DC activation assays, have to be limited to avoid solvent specific effects or cell activation. Thus 
the solvent concentration could not be increased to dissolve substances with low solubility. Three test 
substances had to be excluded from the testing in the DC activation tests due to precipitation, and two more due 
to technical reasons and interference with the measuring device. Formation of DNCB conjugates failed 
presumed with the presence of DMSO and probably interferences with the reaction conditions required to form 
stable conjugates. So far no other vehicles like ethanol, acetone or acetonitrile have been tested on these test 
systems to omit use of DMSO in such cases. Nevertheless, most solvents trigger activation of cells if applied at 
higher concentrations. Alternatively to the increase of solvent concentration the substance could be applied as a 
saturated solution or by passive dosing using a silicon ring saturated with the test substance and applied to the 
cell culture. Thus the use of solvent during the treatment can be avoided (Kramer et al. 2010; Smith et al. 
2010a; Smith et al. 2010b; Tanneberger et al. 2010).  
The effect of the test substances on cell viability (CV) is of great importance. Cytotoxicity can cause non-
specific effects and artifacts and the neglect of cytotoxic effects may yield false positive results. As an example, 
the Keap1-Nrf2-ARE signaling pathway is responsive to oxidative stress, e.g. due to the appearance of ROS, as 
well as to electrophilic chemicals. Thus, non-sensitizers may activate an alternate pathway, also known as 
rescue pathway for cells (Dinkova-Kostova et al. 2005; Wakabayashi et al. 2004; Wang and Jaiswal 2006), as 
response to stress and the threat of cell death rather than in response to the sensitizing potential of the chemical. 
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Additionally, some substances showed dose dependent activity in the reporter gene or DC activation assay albeit 
accompanied by effects on CV. These so-called borderline substances are difficult to interpret and the definition 
of CV thresholds is obligatory as a quality criterion. Literature describes such threshold for the herein used 
assays and substance concentrations reducing CV below 70 % (e.g. KeratinoSens, LuSens and MUSST) or 50 % 
(h-CLAT) should be excluded from evaluation to avoid false positive predictions (Ashikaga et al. 2006; Natsch 
et al. 2011; Nukada et al. 2011; Python et al. 2007). In addition to this the choice of an appropriate assay to 
determine CV is of equal importance and may influence the result. For instance DNA of dead cells can be 
stained with propidium iodide or 7-aminoactinomycin, both that permeate through the porous membrane of dead 
cells but not into living ones. Based on this principle the identification the exclusion of dead cells is performed. 
Assess of metabolic activity, e.g. with substrate the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide, or widely known as MTT substrate, indicates the relative number of living cells. The MTT substrate is 
actively converted by enzymes in Mitochondria into its purple formazan salt with a measureable absorbance at 
490 nm. Thus the increase of formazan and the related increase of absorbance is in proportion with the number 
of living cells. Although interferences may occur with colored test substances or reducing properties of the 
chemicals this assay is widely used for adherent cells (Carmichael et al. 1987; Wang et al. 2010). Those side 
effects could be easily excluded by means of preliminary test with cell free samples.  
The selection of the cell model is dependent on prerequisites like availability of primary human samples, like 
peripheral blood, or permission to work with such material. Although primary cells may represent a more 
reliable model, the use of stable cell lines is for above mentioned reasons more convenient and ensures in 
addition more stable results. Nevertheless cell lines have some disadvantages such as the lack of metabolic 
capacity. This needs to be considered since some chemical sensitizers are pro-haptens as described above. 
Solutions were already described in the literature to address this by adding so-called S9 mix extracted from rat 
hepatocytes (Chipinda et al. 2011) or a skin like cocktail of recombinant enzyme (Bergstrom et al. 2007). The 
benefit of metabolic capacity of KC can be utilized in co-culture with DC (Hennen et al. 2011; Schreiner et al. 
2007). Several markers are available for DC activation like release of cytokines (IL-1α/β or TNFα), a range of 
cell surface makers and the ability of DC to migrate towards different chemokines chemokines as a result of 
chemokine receptor expression (Ouwehand et al. 2010). Not every cell line is able to express those markers as a 
result of DC activation and some show a remarkable level of expression even in their immature state (e.g. U-937 
cells and CD54 (Huang et al. 2001)). The robustness of each assay is correlated with the selected marker, which 
needs to be shown in validation studies as described in this work (see chapters 4,5,6). To address this, the 
selection of chemicals used in optimization and validation is important and should reflect a wide range of 
sensitizers, from weak to extreme as well as prohaptens, non-sensitizers and irritants. Thus weaknesses of the 
selected marker, cell line or assay can be detected. 
  
105 
 
9 CONCLUSION 
The work for this dissertation investigated on animal-free test methods to assess for skin sensitizing potential of 
chemicals. ACD and especially the sensitization process triggered by chemical allergens are complex not only 
due to several, consecutive steps and this is described as well as the AOP of skin sensitization. The presented 
assays can be directly addressed to different steps of this mentioned AOP. The DPRA and computer based 
analysis with the OECD OSAR toolbox reflect the protein reactivity and haptenization of chemical sensitizer 
and proteins. The response of KC and their subsequent activation is mirrored with the reporter gene analysis in 
the KC cell assay KeratinoSens and LuSens. With the DC cell like activation assays MUSST and h-CLAT is the 
activation and maturation of DC addressed. The validity, reliability and reproducibility of these assays was 
shown for more than 50 chemicals and indicated an accuracy greater than 76 % for every assay. The cell based 
assays (KeratinoSens, LuSens, MUSST and h-CLAT) benefit from the use of cell lines instead of primary cells. 
Not only the limited availability of primary cells also the donor-to-donor variability is avoided with the use of 
stable cell lines and thus robust and reliable test systems are provided. Nevertheless changes in sensitivity may 
occur over the time of cell maintenance and with increasing passage number and records to background signals, 
constitutive expressed proteins and the use of positive control and , although not essential, negative control 
substances ensure high quality and reliability of results.  
The formation of protein conjugates with chemicals sensitizers is crucial as no cell response and activation of 
DC can be triggered without, although very little is known about the target protein. With the DPRA and its high 
predictivities and the investigations on the haptenization of cell surface proteins it can be presumes that not only 
the haptenization but also the internalization of conjugated protein may be involved in activation of DC. 
Nevertheless this needs to be further investigated with more test substances and an alternative protein 
determinant, whose expression is not regulated during the process of maturation of DC.  
With one in vitro assay the process of skin sensitization is not sufficiently reflected, but with the combinations 
of those assays into testing strategies a closer simulation of the in vivo process is allowed. It was shown that 
with combination of three assays an increase in predictivities can be achieved. The proposed test strategy which 
combines peptide binding with KC activation and evaluates DC activation using MUSST yielded in the highest 
predictivity with an accuracy of 94% and only three false predicted substances. One important feature in the 
assessment of the skin sensitizing potential is missing in the presented testing strategy: assessment of sensitizing 
potency. Till now only a binary answer only (sensitizer yes/no) is provided by this in vitro test strategy. 
Nevertheless, this work took some important steps towards the use animal-free methods for hazard identification 
of skin sensitizers and the replacement of the current existing animal models, although no regulatory acceptance 
was obtained yet for any of the here mentioned methods.  
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13 APPENDIX 
13.1 ABBREVIATIONS 
3R Reduction, Refinement, Replacement 
ACD allergic contact dermatitis 
AOP Adverse outcome pathway 
APC antigen presenting cell 
ARE antioxidant response element 
BrdU 5-Brom-2-desoxyuridin 
CCR C-C chemokine receptor 
CESAR Computer assisted Evaluation of industrial chemical Substances According to Regulation 
CV Cell viability 
iDC Immature dendritic cell 
DMSO dimethyl sulfoxide 
DNCB 1-chloro-2,4-dinitrobenzene 
DPRA direct peptide reactivity assay 
DST Dermal sensitization threshold 
ECHA european chemical agency 
ECVAM European Centre for Validation of Alternative Methods 
EPA Evironmental Protection Agency 
FDA US Food and Drug Administration 
GARD genomic allergen rapid detection test 
GSH glutathione 
GPMT guinea pig maximization test 
h-CLAT human cell line activation test 
HPLC-UV High pressure liquid chromatography with ultraviolet detection 
ICCVAM Interagency Coordinating Committee on the Validation of Alternative Methods  
ICAM-1 Intercellular Adhesion Molecule 1 
IL Interleukin  
ITS Integrated testing strategy 
KC keratinocyte 
Keap1 Kelch-like ECH associated protein-1  
LC Langerhans’ cells 
LC-MS liquid chromatgraphy – mass spectrometry 
LLNA local lymph node assay 
MHC major histocompatibility complex 
MUSST Myeloid U937 skin sensitization test 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid 
NC3R National Centre for the Replacement, Refinement and Reduction of Animals in Research 
NCA Netherlands Centre Alternatives to Animal Use 
NFκB nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells 
Nrf2 Nuclear factor (erythroid derived 2)like 2 
OECD Organization for economic co-operation and development 
QSAR quantitative structure-activity relationship 
REACH Registration, Evaluation, Authorisation of Chemicals  
RHE reconstructed human epidermis 
ROS reactive oxygen species 
123 
 
SDS sodium dodecyl sulfate 
SI stimulation indices 
SN2/AR nucleophilic (aromatic) substitutions 
TCR T cell receptor 
TNFα Tumor necrose factor α 
TTC Threshold of Toxicological concern  
UV-HPLC Ultra violet- high pressure liquid chromatography 
WoE Weight of Evidence 
ZEBET 
Zentralstelle zur Erfassung und Bewertung von Ersatz- und Ergänzungsmethoden zum 
Tierversuch 
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